Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 17 |
| Active Pipeline (Recruiting Now) | 4 (1) |
| Completed vs Stopped Early | 10 / 3 (17.6%) |
| Median Closed Actual Enrollment | 16 participants |
| Physical Hospital Site Disclosure | 85.7% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Fukushima Medical University Hospital | Fukushima | 3 |
| MD Anderson Cancer Center | Houston, TX | 2 |
| Mayo Clinic Rochester | Rochester, MN | 2 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06782373 | A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the Swedish Orphan Biovitrum Interactive Dossier, benchmark peers in Rare Genetic, Women's Health, and Other, or review the Healthcare Price & Patent Cliff Crosswalk.